Shares of Marksans Pharma could remain in focus after the company announced that its wholly owned UK subsidiary, Relonchem Limited, has received marketing authorization for Sennosides 7.5 mg tablets from the UK Medicines & Healthcare Products Regulatory Agency (MHRA).
This regulatory clearance marks a significant step in the company’s product expansion in the UK pharmaceutical market. Sennosides are typically used as a laxative in various therapeutic segments, and the approval strengthens Marksans’ position in the gastrointestinal treatment category.
Marksans Pharma, headquartered in Mumbai, engages in the research, manufacturing, and marketing of generic pharmaceutical formulations across global markets. Its manufacturing facilities in India, the USA, and the UK are approved by top regulatory bodies, including USFDA, UKMHRA, and Australian TGA.
The company’s product portfolio spans major therapeutic areas such as cardiovascular, central nervous system, anti-diabetic, pain management, gastroenterological, and anti-allergies.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
